Learn about the latest trends and activities through our blog posts.
We were quoted in Bloomberg Law’s article titled “States Risk Losing Power to Regulate Pharmacy Drug Middlemen” by Lydia Wheeler. The article discusses the pros and cons of Rutledge v. PCMA, which is currently being debated at the Supreme Court.
Read MoreThe Secure and Fair Enforcement Banking Act of 2019 (SAFE Banking Act) is still pending in Congress. Also known as H.R. 1595, the bill proposes to create protections for depository institutions that provide financial services to cannabis-related legitimate businesses and service providers for such businesses.
Read MoreThe Association for Accessible Medicines sent letters to all members of Congress, which expressed what measures they would like them to take regarding access to biosimilars.
Read MoreLast week the National Association of Chain Drug Stores (NACDS), the Washington State Pharmacy Association (WSPA) and the National Community Pharmacists Association (NCPA) celebrated an administrative law judge’s ruling against Washington State that stated Washington’s pharmacy reimbursement plan violated Medicaid’s rules.
Read MoreMany supply chain stakeholders have been fearing whether Amazon would ever open a retail pharmacy business. There have been traces of this occurring for years from its sporadic applications of pharmacy licenses in various states, to its June 2018 $753 million acquisition of PillPak. However; no coherent plan had come into focus until now.
Read MoreIn what has surprised many cannabis stakeholders it seems as though the November 2020 elections is bringing a new therapeutic item into the mainstream healthcare policy conversation: psychedelic mushrooms via ballot box initiatives.
Read MoreThe result of a few November 3, 2020 election ballot measures have yielded additional gains for marijuana.
Read MoreWith increasing mergers and acquisitions in both the technology and healthcare sectors, investment opportunities abound for funds and interested stakeholders. In order for these stakeholders to be successful it is essential to know the limits and opportunities within a complex regulatory landscape.
Read MoreLanton Law believes that the cannabis market will continue to evolve and expand. Notwithstanding this market potential is the fact that medical and adult-use cannabis operations are confronted with a complex patchwork of state and federal laws and regulations that we assist a variety of businesses with.
Read MoreLanton Law had a follow up interview with Law360 regarding the Rutledge v. PCMA Supreme Court oral arguments on October 6, 2020.
Read MoreLanton Law was quoted in Law360’s article titled “High Court to Weight States’ Ability to Rein in Drug Middlemen,” which was written in response to current developments around the Rutledge v. PCMA case.
Read MoreWith election season underway many are wondering where the two Presidential candidates stand on the issues of importance to voters.
Reuters did a great summary found here that explains the major differences from the economy, trade, healthcare, etc.
Read MoreOn September 21st the FDA closed its comment period related to cannabis. Back in July the Food and Drug Administration (FDA) announced the availability of a draft guidance for industry entitled “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.”
Read MoreOn September 13, 2020, the Trump Administration released a new Executive Order (EO) targeting drug pricing.
Read MoreRon Lanton; Principal of Lanton Law addresses the National Association of Specialty Pharmacy on emerging specialty issues.
Read MoreWe have released our August newsletter.
Read MoreThe Long-Term Care Pharmacy Definition Act of 2020 has been introduced by U.S. Senator Scott (R-SC) and co-sponsored by Senator Warner (D-VA). The bill has been introduced in the U.S. House of Representatives by Congressman Mullin (R-OK) and Congressman Schrader (D-OR). The bill seeks to establish a clear statutory definition of long term care pharmacy.
Read MoreDemocrats on the House Energy and Commerce Committee led by Chairman Pallone (D-NJ) along with Congresswoman DeGette (D-CO) Chair of the Subcommittee on Oversight and Investigations, Congresswoman Schakowsky (D-IL) and Congressman Doyle (D-PA) sent a letter to Facebook along with other tech companies requesting more COVID-19 transparency on their platforms. The request seeks monthly reports on this issue which mirrors a similar request from the European Union.
Read More
